Translating the Science of Cancer Dormancy to the Clinic
- PMID: 34429327
- PMCID: PMC8562555
- DOI: 10.1158/0008-5472.CAN-21-1407
Translating the Science of Cancer Dormancy to the Clinic
Abstract
The paradigm of metastasis has been significantly remodeled by the incorporation of cancer dormancy as a mechanism to explain long-term remission intervals followed by relapse. There is overall consensus on the potential impact of better understanding dormancy. Key cancer-cell autonomous and microenvironmental mechanisms might explain this biology and, in turn, the timing of metastasis. However, the approach and feasibility to apply this biology to clinical trials has been controversial. The discussion here provides insight into how these controversies are being resolved by the development of active clinical trials, thus bringing to reality opportunities to target cancer dormancy.
©2021 American Association for Cancer Research.
Conflict of interest statement
Conflict of Interest Statement:
JAAG is a scientific co-founder of, scientific advisory board member and equity owner in HiberCell LLC and receives financial compensation as a consultant for HiberCell, a Mount Sinai spin-off company focused on therapeutics that prevent or delay cancer recurrence.
References
-
- Vessella RL, Pantel K, Mohla S. Tumor Cell Dormancy: An NCI Workshop Report. Cancer Biol Ther 2007;6(9). - PubMed
-
- Aguirre-Ghiso J A; Methods of treating minimal residual cancer. USA 2019. 03.10.2019.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
